Theseus Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a THRX research report →
Price Chart
About the company
Theseus Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and bringing to market targeted treatments for cancer patients. Their leading investigational compound, THE-630, is a pan-KIT inhibitor undergoing Phase I clinical trials for treating gastrointestinal stromal tumors.
- CEO
- Iain D. Dukes DPHIL,
- IPO
- 2021
- Employees
- 38
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on THRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $181.50M
- P/E
- -3.33
- PEG
- 0.21
- P/S
- 0.00
- P/B
- 0.75
- EV/EBITDA
- -1.68
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -20.74%
- ROIC
- -23.73%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-438,000-21800.0%
- Op Income
- $-54,086,000
- Net Income
- $-47,080,000-72.4%
- EPS
- $-1.22-60.5%
- OCF Growth
- -21.2%
- FCF Growth
- -22.9%
- 52W High
- $12.37
- 52W Low
- $2.05
- 50D MA
- $3.95
- 200D MA
- $5.00
- Beta
- 3.98
- RSI (14)
- 60
- Avg Volume
- 849.60K
No earnings-call transcripts are available for THRX yet.
- Free Float
- 31.9%
- Shares Outstanding
- 44.65M
- Float Shares
- 14.26M
of shares held by institutions
72 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Foresite Capital Opportunity Management V, LLC | 959.27K | 0 |
| Tekla Capital Management LLC | 75.00K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 14, 24 | Yi Kathy | sell | 3,250 |
| Feb 14, 24 | Yi Kathy | sell | 99,634 |
| Feb 14, 24 | Stein Steven H | sell | 3,250 |
| Feb 14, 24 | ORBIMED ADVISORS LLC | other | 650,600 |
| Feb 14, 24 | HAYDEN DONALD J JR | other | 10,000 |
| Feb 14, 24 | HAYDEN DONALD J JR | sell | 3,250 |
| Feb 14, 24 | GORDON CARL L | other | 650,600 |
| Feb 14, 24 | GORDON CARL L | sell | 3,250 |
| Feb 14, 24 | Dukes Iain D. | other | 388,324 |
| Feb 14, 24 | Dukes Iain D. | sell | 61,549 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our THRX coverage
Recent articles, reports, and earnings notes.
No research on THRX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate THRX report →Theseus Pharmaceuticals Announces Closing of Tender Offer
prnewswire.com · Feb 14
THESEUS PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Theseus Pharmaceuticals, Inc. - THRX
prnewswire.com · Jan 22
THESEUS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Theseus Pharmaceuticals, Inc. - THRX
businesswire.com · Dec 31
Is Theseus Pharmaceuticals (THRX) Stock a Solid Choice Right Now?
zacks.com · Dec 29
Shareholder Alert: Ademi LLP investigates whether Theseus Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Concentra
prnewswire.com · Dec 22
THRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Theseus Pharmaceuticals, Inc. Is Fair to Shareholders
businesswire.com · Dec 22
Theseus Pharmaceuticals Enters into Agreement to Be Acquired by Concentra Biosciences for between $3.90 and $4.05 in Cash per Share Plus a Contingent Value Right
prnewswire.com · Dec 22
Theseus (THRX) Up 57% in a Month on Strategic Restructuring Plan
zacks.com · Nov 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.